Oncology Medical News about early-stage breast cancer;partial breast irradiation;dose-dense Coxorubicin and Cyclophosphamide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
Journal of Clinical Oncology, 06/10/09

Zellars RC et al. - In a study to determine whether anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) are safe, it was shown that PBI with concurrent dose-dense doxorubicin and cyclophosphamide (ddAC) is feasible, and local/systemic toxicity is acceptable.

Methods

Women with T1-2, N0-1 breast cancer with ≥3 mm lumpectomy margins received PBI (40.5 Gy, 15 daily 2.7-Gy fractions) concurrently with the first 2 of 4 cycles of ddAC (60 and 600 mg/m2 of doxorubicin and cyclophosphamide, respectively, every 14 days with colony-stimulating support).
Primary endpoints were local and systemic toxicity.
Additional systemic therapy was given at the physician's discretion.

Results

27 pts enrolled, but 2 pts did not receive protocol therapy (1 found with additional local disease and 1 withdrew consent).
25 women completed all planned PBI.
4 (16%) of 25 did not complete all ddAC (febrile neutropenia [FN], n=2; diverticulitis and neutropenia, n=1; and social/economic reasons, n=1).
4 of the remaining 21 who completed all ddAC had a cycle delayed (FN, n=1; acute respiratory illness, n=1; foot blisters, n=1; perianal dermatitis, n=1).
There was no grade 3 to 4 anemia or thrombocytopenia.
Grade 3 nonhematologic toxicities (none grade 4) occurred in 28% (7 of 25) of pts (nausea/vomiting, n=3; stomatitis, n=2; contralateral breast abscess, n=1; fatigue, n=1; and cough/bronchospasms, n=1).
observed rate of ≥ grade 2 skin toxicity was 0% (0 of 25).

<< Previous
Infection Control Cutbacks Cost Patients and Hospitals

Next >>
Ki67 expression and docetaxel efficacy in patients with estrogen...

Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: A prospective randomised multicentre trial
The Breast, 11/16/09 Relevance Score: 82%%

Rethinking Screening for Breast Cancer and Prostate Cancer
JAMA, 10/23/09 Relevance Score: 82%%

Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer
Breast Cancer Research and Treatment, 10/13/09 Relevance Score: 82%%

Original contribution: association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
JAMA, 10/07/09 Relevance Score: 82%%

Enzyme Variation Influences Effectiveness of Breast Cancer Treatment
Ivanhoe, 10/13/09 Relevance Score: 81%%